Valero C, Pardo L, Sansa A, et al. - Given the proposed value of Systemic Inflammation Response Index (SIRI) as a pretreatment peripheral blood biomarker, researchers examined its prognostic capacity in head and neck squamous cell carcinomas (HNSCC). A retrospective study of 824 patients with HNSCC was conducted. They identified a significantly higher SIRI value among males, patients with a history of toxic consumption, oropharyngeal or hypopharyngeal tumors, and advanced tumors. They observed a significant decrease in disease-specific survival (DSS) with an increase in SIRI. Multivariable analysis suggest the independent value of SIRI for predicting DSS. Furthermore, they observed a significant predictive value of SIRI for local, regional, and distant recurrence-free survival.